Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of breast cancer that lacks the estrogen, progesterone and HER2 receptors and is resistant to targeted and hormone therapies. TNBCs express high levels of the transmembrane glycoprotein, complement C1r/C1s, Uegf, Bmp1 (CUB)-domain containing protein 1 (CDCP1), which has been correlated with the aggressiveness and poor prognosis of multiple carcinomas. Full-length CDCP1 (flCDCP1) can be proteolytically cleaved, resulting in a cleaved membrane-bound isoform (cCDCP1). CDCP1 is phosphorylated by Src family kinases in its full-length and cleaved states, which is important for its pro-metastatic signaling. We observed that cCDCP1, compared with flCDCP1, induced a dramatic increase in phosphorylation of the migration-associated proteins: PKCδ, ERK1/2 and p38 mitogen-activated protein kinase in HEK 293T. In addition, only cCDCP1 induced migration of HEK 293T cells and rescued migration of the TNBC cell lines expressing short hairpin RNA against CDCP1. Importantly, we found that only cCDCP1 is capable of dimerization, which can be blocked by expression of the extracellular portion of cCDCP1 (ECC), indicating that dimerization occurs through CDCP1's ectodomain. We found that ECC inhibited phosphorylation of PKCδ and migration of TNBC cells in two-dimensional culture. Furthermore, ECC decreased cell invasiveness, inhibited proliferation and stimulated apoptosis of TNBC cells in three-dimensional culture, indicating that the cCDCP1 dimer is an important contributor to TNBC aggressiveness. These studies have important implications for the development of a therapeutic to block CDCP1 activity and TNBC metastasis. 
INTRODUCTION
Breast cancer is the second leading cause of death of women in the United States; most of these fatalities are caused by metastatic disease. Many therapies have been developed to target aggressive breast cancer, including receptor-targeted therapies (Herceptin) and anti-hormone therapies (aromatase inhibitors). However, triple-negative breast cancer (TNBC) patients are not candidates for many of these therapies, as they do not express the respective drug targets, HER2, estrogen and progesterone receptors. Moreover, TNBC is a highly aggressive form of breast cancer that is associated with advanced stage at diagnosis, early peak of recurrence and poorer outcome in comparison with non-TNBCs; in the advanced setting, responses to chemotherapy and radiation therapy lack durability. 1 Finally, women who are diagnosed with TNBC tend to be younger than non-TNBC patients. Thus, there is an urgent need to develop a targeted therapy to inhibit the progression and metastasis of TNBC.
The transmembrane protein, complement C1r/C1s, Uegf, Bmp1 (CUB)-domain containing protein 1 (CDCP1), is upregulated in TNBC and is correlated with the cancer's aggressiveness. 2 Importantly, CDCP1 is involved in metastasis in multiple animal models of cancer, including lung adenocarcinoma, gastric scirrhous carcinoma, melanoma, and prostate and ovarian carcinomas. [3] [4] [5] [6] [7] [8] [9] CDCP1 expression is induced by hypoxia in clear-cell renal cell carcinoma (ccRCC) 10, 11 and activated Ras in lung cancer, 12 and its localization at the membrane is induced by epidermal growth factor receptor in ovarian cancer. 13 The full-length, 135-kDa CDCP1 protein (flCDCP1) can be cleaved into a 70-kDa, membrane-bound cleaved CDCP1 (cCDCP1) and a 65-kDa portion that is shed on the extracellular side of the membrane. CDCP1 can be cleaved by plasmin, trypsin and matriptase, 8, 14, 15 and evidence is growing to support the necessity of CDCP1 cleavage for its activity. 2, 3, 8, 16 In addition to cleavage, CDCP1 activity depends on phosphorylation; both flCDCP1 and cCDCP1 are phosphorylated by Src family kinases, Src, Fyn and Yes, first at Y734 and then at Y743, Y762, Y707 and Y806. 4, 14, [17] [18] [19] [20] [21] [22] [23] CDCP1 can stimulate migration/ invasion through a variety of signaling pathways including protein kinase C δ (PKCδ), 10, 24 protein kinase B (Akt), 3, 8, 9 β 1 integrin, 3 matrix metalloproteinase secretion 25 and others. Besides its well established role in cancer cell migration, CDCP1 was reported to degrade adherens junctions, 2, 18 protect against anoikis 4 and inhibit autophagy, 26 contributing to tumor progression. CDCP1 contains three CUB domains located in its ectodomain, the specific role of which remains unclear. CUB domains are expressed in many developmentally regulated proteins and participate in interactions with CUB domains of other proteins. 27 The first CUB domain is removed by CDCP1 cleavage, potentially stimulating important protein-protein interactions through CUB2 and CUB3, leading to the enhancement of CDCP1 signaling. Casar et al. 3, 8 recently reported a decrease in metastasis with inhibition of CDCP1 cleavage, hinting at the necessity of cleavage for CDCP1 activity. In support of this, Law et al. 2 showed that inhibition of CDCP1 cleavage refined the borders of ex vivo tumors, proposing the inhibition of CDCP1 cleavage as a rational neoadjuvant therapy for TNBC. Although these data indicate that CDCP1 cleavage stimulates its activity, the mechanism of cCDCP1 activation has not been elucidated.
Here we demonstrate that CDCP1 expression is upregulated in TNBC and it is cleaved and phosphorylated in TNBC cell lines and primary TNBC specimens. We find that CDCP1 cleavage leads to cCDCP1 homodimerization, uncovering the mechanism of cCDCP1 activation. The homodimer acts as a docking station for Src to induce phosphorylation of a key CDCP1 downstream target, PKCδ, stimulating pro-migratory signaling. We provide evidence that dimerization is a key step in CDCP1 activation by breaking the dimer with the extracellular portion of cCDCP1 (ECC), which blocks CDCP1's downstream signaling, leading to inhibition of migration, invasion, proliferation, and induction of apoptosis. Therefore, CDCP1 dimerization is a rational target for therapeutic intervention to inhibit metastasis of TNBC.
RESULTS

CDCP1 is overexpressed and cleaved in TNBC
The data acquired from The Cancer Genome Atlas (TCGA) (http:// cancergenome.nih.gov/) indicated that CDCP1 mRNA is upregulated in TNBC compared with normal breast tissue (Figure 1a ), suggesting CDCP1's role in breast cancer progression. Consistent with the data extracted from TCGA, we found that the average CDCP1 expression in MDA-MB-231, MDA-MB-453, MDA-MB-468 and UCI-082014 (Supplementary Table 1 ) TNBC cells was 1.8-fold higher than the average expression in primary mammary epithelium and immortalized non-tumorigenic MCF10A breast cells (Figure 1b) .
Recent reports indicated that cleavage stimulates CDCP1 protein activity. 2, 3, 8, 16 Figure 1b shows that CDCP1 is highly cleaved in all of the TNBC cell lines listed above (54% cleaved) compared with primary mammary epithelium and MCF10A cells, where CDCP1 exists primarily in the full-length form (12% cleaved). We also found that CDCP1 is cleaved in the non-TNBC cell line derived from a brain metastasis, MDA-MB-361 (Figure 1b) . Furthermore, we found that eight out of eight TNBC patient samples analyzed by western blotting (WB) express CDCP1, which is mostly cleaved and phosphorylated (Figure 1c and Supplementary Figure 1) .
Previously, we and others showed that CDCP1 expression was regulated by hypoxia-inducible factors in ccRCC. 10, 11 As breast tumors contain areas of low oxygen tension, 28 we investigated whether CDCP1 is regulated by hypoxia in the TNBC cell line MDA-MB-231. We found that although the mRNA and protein levels of CDCP1 were not upregulated in hypoxia, the phosphorylation of cCDCP1 and its downstream target PKCδ were increased in hypoxia, indicating that CDCP1 activity increases (Supplementary Figure 2) .
Both flCDCP1 and cCDCP1 interact with PKCδ and Src but only cCDCP1 stimulates downstream signaling To test the functional difference between flCDCP1 and cCDCP1 we created Flag-tagged constructs of each CDCP1 isoform (Supplementary Figure 3) . The signal peptide (SP) located at the CDCP1 is mostly full-length in primary mammary epithelium (PME) cells and the immortalized non-tumorigenic breast cell line, MCF10A, and is mostly cleaved in TNBC cell lines and metastatic non-TNBC cells, MDA-MB-361. Quantified percent of CDCP1 cleavage was obtained by band densities in ImageJ (top row) = cCDCP1/(cCDCP1+flCDCP1)*100. Quantified relative CDCP1 expression was obtained from band densities in ImageJ (bottom row) = (flCDCP1+cCDCP1)/β-actin, CDCP1 expression in PME was normalized to 1 and all other lanes were normalized to that for comparison. (c) Primary human TNBC samples express cleaved and phosphorylated CDCP1. Equal protein amounts were loaded in each lane. cCDCP1 activity depends on homodimerization HJ Wright et al N-terminus of flCDCP1 was added at the N-terminus of cCDCP1 to ensure proper localization. We overexpressed a vector control (VC), cCDCP1-Flag or flCDCP1-Flag in HEK 293T cells, which do not express endogenous CDCP1 and do not cleave exogenous flCDCP1. As expected, immunostaining confirmed that both CDCP1 isoforms localized on the cell membrane (Supplementary Figure 4) . We found that although both isoforms of CDCP1 could be phosphorylated at Y734, only cCDCP1 could induce robust phosphorylation of its downstream target PKCδ, as well as ERK1/2 and p38 mitogen-activated protein kinase, other kinases known to be involved in migration 29 ( Figure 2a) . Interestingly, previous findings indicate that CDCP1 expression is regulated by ERK1/2 signaling downstream of Ras in non-small cell lung carcinoma, 12 suggesting a potential positive feedback loop between CDCP1 and ERK1/2. Based on previous reports that CDCP1 binds Src and PKCδ, stimulating PKCδ phosphorylation by Src at Y311, 4, 8, 10, 16, 20, 24 we compared the ability of both CDCP1 isoforms to associate with Src and PKCδ. We immunoprecipitated each CDCP1 isoform by Flag tag and probed the membrane with antiSrc and anti-PKCδ antibodies. We found that both flCDCP1 and cCDCP1 could associate with Src and PKCδ. However, only cCDCP1 co-precipitated phosphorylated PKCδ ( Figure 2b ). As Law et al. 2 demonstrated the ability of dexamethasone to inhibit CDCP1 cleavage in TNBC cells, we treated MDA-MB-231 cells with a phosphate-buffered saline (PBS) vehicle control or 100 nM dexamethasone for 48 h. We found that inhibiting CDCP1 cleavage in TNBC cells inhibited PKCδ phosphorylation (Figure 2c ). These data indicate the necessity of CDCP1 cleavage for signaling through PKCδ. cCDCP1 stimulates cell migration Owing to the ability of cCDCP1 to induce robust phosphorylation of PKCδ, which we have previously linked to pro-migratory signaling, 10 we aimed to analyze the effect of each CDCP1 isoform on cellular migration. To do this, we overexpressed VC, cCDCP1-Flag or flCDCP1-Flag in HEK 293T cells and analyzed migration through fibronectin-coated transwell inserts after 24 h. We found that cCDCP1 significantly induced migration of HEK 293T cells, whereas flCDCP1 did not (Figure 3a) .
Based on these data and the high level of CDCP1 cleavage in MDA-MB-231 cells (Figures 1b and 2a) , we assessed the contribution of cCDCP1 in MDA-MB-231 cell migration in a scratch assay. We knocked down endogenous CDCP1 with two short hairpin RNAs (shRNAs) targeting two different sites on CDCP1's . We validated these data in another TNBC cell line, MDA-MB-468, where CDCP1 knockdown inhibited migration through fibronectin-coated transwell inserts, which was rescued by cCDCP1 and not sh-ins-ncCDCP1 overexpression ( Figure 3c ).
cCDCP1 forms a dimer independently of its phosphorylation status CUB domains have known roles in protein-protein interaction [30] [31] [32] including the potential CUB domain-CUB domain interaction of CDCP1 with matriptase. 14 flCDCP1 has three CUB domains (1, 2 and 3) and cCDCP1 has two CUB domains (2 and 3). Thus, we decided to test whether either isoform of CDCP1 could form a dimer. To do this, we created C-terminal His-tagged cCDCP1 and flCDCP1 constructs. We overexpressed Flag-and His-tagged CDCP1 constructs alone or in combination in HEK 293T cells (Figure 4a ). The Flag tag was immunoprecipitated and dimerization was analyzed by immunoblotting for the His tag. Our results indicate that only cCDCP1 could form a dimer ( Figure 4a ).
As interactions of CDCP1 with other proteins at the membrane are dependent on its phosphorylation, 3, 4, 15, 20, 33 we analyzed the dependency of the dimer on CDCP1's phosphorylation status. To do this, we created cCDCP1-Y734F-Flag and cCDCP1-Y734F-His constructs, which are phosphorylation incompetent (Supplementary Figure 6) . We then repeated co-immunoprecipitation experiments in HEK 293T cells by expressing Flag-and His-tagged constructs of cCDCP1 and cCDCP1-Y734F alone or in combination and found that cCDCP1 was capable of forming a dimer independently of its phosphorylation status. However, overexpression of cCDCP1 Y734F-Flag did not stimulate phosphorylation of PKCδ at Y311 (Figure 4b ).
To determine whether CDCP1 forms a dimer endogenously in TNBC cells, we used the Duolink proximity ligation assay. We found that CDCP1 formed a dimer in MDA-MB-231 cells visualized by the red punctate signal (Figure 4c ). This signal was lost in MDA-MB-231-shCDCP1-1 cells and regained on rescue with cCDCP1 overexpression, but not with sh-ins-ncCDCP1 ( Figure 4c and Supplementary Figure 7) . An extracellular fragment of cCDCP1 can block the cCDCP1 dimer formation Based on the above data, we propose that cCDCP1 forms a dimer through its extracellular domain, specifically through one or both of its CUB domains. To test this hypothesis, we made a construct expressing the ECC with an N-terminal SP and a C-terminal His tag (Figure 5a (i) ). To monitor CDCP1 dimerization, we used a firefly split-luciferase system 34 in which the N-terminal domain or C-terminal domain of firefly luciferase was attached to the intracellular C-terminus of cCDCP1, resulting in cCDCP1-N'luc and cCDCP1-C'luc constructs, respectively (Figure 5a (ii and iii) ).
We also created flCDCP1-N'luc and flCDCP1-C'luc constructs. Using the split-luciferase system in HEK 293T cells we confirmed that only cCDCP1, not flCDCP1, forms a dimer and no heterodimer is formed between cCDCP1 and flCDCP1 (Figure 5b and Supplementary Figure 8) . Next, we expressed the cCDCP1-N'luc and cCDCP1-C'luc constructs in combination with VC or ECC. Importantly, ECC was able to decrease the D-luciferin luminescence, indicating blockage of the cCDCP1 dimer formation (Figure 5b ). The observed effect of ECC on cCDCP1 dimer blockage is specific, as ECC had no effect on cCDCP1 expression or luciferase enzyme activity (Supplementary Figure 9) . As ECC has a SP at its N-terminus, which is necessary for secretion, 14 we found secreted ECC in the media of transfected HEK 293T cells (Figure 5c ).
To validate the importance of the cCDCP1 dimerization in promigratory signaling, we analyzed the effect of ECC on PKCδ phosphorylation and migration of MDA-MB-231 cells. We found that overexpressing ECC in MDA-MB-231 cells inhibited PKCδ phosphorylation (Figure 5d ). We further found that transfer of ECC-conditioned media from ECC-transfected HEK 293T cells to MDA-MB-231 cells inhibited their migration (Figure 5e ). We also validated the inhibitory effect of ECC on migration through transwell inserts using two additional TNBC cell lines, MDA-MB-468 and UCI-082014, expressing either VC or ECC (Figure 5f and g ). Together, these data validate that cCDCP1 dimerization facilitates PKCδ phosphorylation and stimulates cell migration.
ECC inhibits TNBC cell invasiveness, decreases proliferation and induces apoptosis in 3D culture
To analyze the effect of ECC on TNBC cells in three dimensions (3D), 35 we cultured MDA-MB-231, MDA-MB-468 and UCI-082014 36-38 Staining of ECC using an anti-His-tag antibody revealed that after secretion, ECC concentration builds around the cells (Supplementary Figure 10) , probably leading to saturation of cCDCP1 dimer inhibition at the membrane. Thus, the cCDCP1 inhibition by ECC leads to a more dramatic phenotype in 3D as opposed to two-dimensional culture, where ECC is secreted into the culture media.
DISCUSSION
Our studies have elucidated a new step in the CDCP1 activation cascade: cCDCP1 homodimerization, which is critical for phosphorylation of PKCδ and migration of TNBC cells. Figure 7 illustrates an updated model for CDCP1 activation, including its phosphorylation, cleavage and dimerization. We suggest that the cCDCP1 dimer acts as a docking station to facilitate PKCδ phosphorylation by Src: cCDCP1 dimer is important for binding of Src to one subunit and PKCδ to the other subunit, bringing Src and PKCδ into close proximity, allowing the phosphorylation of PKCδ by Src. This signaling cascade further leads to phospho-PKCδ-stimulated migration. Our model also explains the ability of flCDCP1 to bind to Src and PKCδ without stimulating PKCδ phosphorylation: Src and PKCδ are not bound to flCDCP1 at the same time. These data are in line with ex vivo data in TNBC 2 and in vivo data in prostate cancer, 3, 8 showing that CDCP1 cleavage is required to induce cellular dissemination and multiple-organ metastasis. Although the positive and negative regulators of CDCP1 dimerization remain to be elucidated, we have shown that ECC represents a way to inhibit dimerization of cCDCP1, disrupting cCDCP1 pro-migratory signaling.
Our data in 3D showing an increase in ECC-expressing TNBC cell apoptosis are in line with previous studies demonstrating that CDCP1 knockdown by si/shRNA induces apoptosis in lung and breast cancer cells cultured in anchorage-free conditions, 4 ,39,40 a study showing that inhibition of CDCP1 cleavage in vivo induced apoptosis of prostate cancer cells 8 and studies demonstrating that a function-blocking antibody against CDCP1 inhibited cell invasiveness in a 3D culture system and tumor growth in a xenograft model of breast cancer. 41, 42 The induction of apoptosis in the presence of extracellular matrix components, collagen I and Matrigel (collagen IV, laminin, enactin/nidogen-1 and proteoglycans), may indicate that ECC inhibits stellate structure formation, which is indicative of cell binding and anchoring to these substrates during invasion. This explanation is supported by a study showing preferential and direct binding of β 1 integrin to cCDCP1 over flCDCP1. 3 Our data suggest that cCDCP1 may promote β 1 integrin activity, which is inhibited in the presence of ECC. It also remains to be investigated whether ECC is specific to the cCDCP1 homodimer or also inhibits cCDCP1 interactions with other proteins. The increased efficacy of ECC in 3D culture remains to be validated in an orthotopic mouse model of TNBC, where we expect the same accumulation of ECC extracellularly to inhibit cell-extracellular matrix adhesion, proliferation and induce apoptosis.
The ability of CDCP1 to form a dimer is supported by previous findings that treatment of NIH3T3 and MCF7 cells overexpressing exogenous CDCP1 with a bivalent anti-CDCP1 antibody stimulates CDCP1 activity, presumably by stimulating its clustering in lipid rafts. 41 Kollmorgen et al. 22 proposed that CDCP1 forms a dimer through the transmembrane or intracellular dimer interface but they did not investigate the dependence of dimer formation on CDCP1 cleavage. Although we do not exclude the possibility that CDCP1 forms a dimer through transmembrane or intracellular domains as well, our data support dimer formation through the extracellular CUB domains, with the secreted ECC portion capable of inhibiting dimerization of cCDCP1. Our data show that cCDCP1 forms a dimer, although we do not exclude the possibility that it is capable of forming a tetramer or higher molecular complex. Further research is needed to test this possibility.
It remains to be investigated how flCDCP1 stimulates signaling through PKCδ in ccRCC. For instance, 786-0 cells express almost exclusively flCDCP1 and we have shown previously that flCDCP1 stimulates migration of ccRCC cells through PKCδ. 10 One striking difference between ccRCC and TNBC lies in abundance of lipid droplets, which is extremely high in ccRCC 43 and rather low in TNBC. 44, 45 As CDCP1 is present in Triton X-100-insoluble lipid rafts, 25, 41 we propose that the high lipid content of ccRCC cells facilitates clustering of flCDCP1 at the membrane in lipid rafts, which leads to stimulation of PKCδ phosphorylation by Src. On the other hand, TNBC relies on CDCP1 cleavage to induce cCDPC1 dimerization to stimulate PKCδ phosphorylation by Src. In line with this, Casar et al. 3, 8 showed that PC3 and HEK 293T cells, which have low lipid content, 46, 47 are dependent on CDCP1 cleavage for cellular dissemination in vitro, in chick embryo and mouse models of metastasis.
Although we found that CDCP1 is not hypoxia inducible at the mRNA and protein levels in TNBC, the phosphorylation of cCDCP1 and PKCδ are hypoxia inducible. Importantly, we 10 and others 11 have shown that CDCP1 is hypoxia inducible through the hypoxia inducible factor pathway at the mRNA and protein levels in ccRCC. Cell-type-specific hypoxic induction of hypoxia inducible factor target genes has been described previously, 48 which could explain the discrepancy between ccRCC and TNBC. Emerling et al. 11 demonstrated that Src Y416 and CDCP1 Y734 phosphorylation are hypoxia inducible in ccRCC, which we replicated in TNBC. The mechanism of stimulation of these types of phosphorylation under hypoxia deserves further investigation.
The CDCP1 signaling cascade has not been investigated in depth in TNBC and other types of breast cancer. It was previously reported that cCDCP1 promotes TNBC migration by sequestering E-cadherin intracellularly 2 and TNBC invasion by stimulating membrane type 1 matrix metalloproteinase activity. 25 Our studies suggest that cCDCP1 promotes TNBC migration through dimerization, which is important for PKCδ phosphorylation and potentially ERK1/2, and p38 mitogen-activated protein kinase phosphorylation (requires further investigation). In addition, it was (3) cCDCP1 is capable of forming a dimer, which allows SFKs and PKCδ to bind to each individual subunit of a dimer, leading to PKCδ phosphorylation by SFKs. Activated PKCδ induces pro-migratory signaling. ECC is capable of inhibiting cCDCP1 dimerization, PKCδ phosphorylation and migration of TNBC cells. We propose that targeting CDCP1 dimerization will lead to blockade of SFK/PKCδ signaling and inhibit CDCP1-mediated migration and invasion in TNBC. Black arrows, phosphorylation by SFKs; gray arrows, binding; blue, CUB domains; red, binding site; P in red circle, phosphorylation.
cCDCP1 activity depends on homodimerization HJ Wright et al recently shown that CDCP1 directly interacts with HER2 and stimulates progression of HER2-positive tumors. 49 On the other hand, a correlation between estrogen and progesterone receptor status and CDCP1 expression has not been found. 50 Thus, the dependence of CDCP1 activity on cleavage and dimerization in hormone receptor-positive breast cancers remains to be investigated.
Our data validate the previously demonstrated therapeutic potential of targeting the cleaved isoform of CDCP1 to inhibit cancer metastasis. 3 However, we provide novel insight into the CDCP1 activation mechanism and propose targeting a step downstream of CDCP1 cleavage: dimerization.
MATERIALS AND METHODS
Cell lines and media HEK 293T, MDA-MB-231, MDA-MB-453, MDA-MB-468 and MDA-MB-361 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM; Genesee, San Diego, CA, USA; #25-500) with 10% fetal bovine serum (FBS; Omega Scientific, Tarzana, CA, USA; #FB-12), 2 mM L-glutamine, 100 µg/ml penicillin and 100 μg/ml streptomycin. Cells were grown in mixed gas CO 2 waterjacketed incubators (21% O 2 and 5% CO 2 ). MCF10A cells were grown in the same media as above supplemented with 20 µg/ml epidermal growth factor (PeproTech, Rock Hill, NJ, USA; #AF-100-15) and 10 μg/ml insulin (Roche, San Francisco, CA, USA; #11376497001). MDA-MB-231 and MDA-MB-468 cell lines, extensively used for in vitro experiments in this study, were validated using short tandem repeat profiling by the American Type Culture Collection (Manassas, VA, USA). All cells were regularly tested for mycoplasma contamination and confirmed to be negative.
Primary specimen acquisition and lysis
Fresh TNBC specimens were acquired from Hoag pathology and frozen on arrival. Frozen TNBC specimens were obtained from the UC Irvine Medical Center. For lysis, specimens were thawed on ice and then homogenized in cell lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Na 4 P 2 O 7 , 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 ) with protease inhibitors (Fisher Scientific, Pittsburgh, PA, USA; #P1-88266) and phosphatase inhibitors (Roche #04906845001).
Western blotting
Protocol was adapted from Razorenova et al. 51 Briefly, cells were lysed using cold cell lysis buffer (see recipe above) with protease inhibitors (Fisher Scientific). Protein was measured using BCA Protein Assay kit (Pierce, Rockford, IL, USA; #PI-23225). Forty micrograms of protein was loaded/lane of 10% bis-acrylamide gels and transferred onto 0.2 μm nitrocellulose membranes (BioRad, Hercules, CA, USA). Membranes were incubated with primary antibodies overnight at 4°C with gentle agitation, then incubated with secondary antibodies for 1 h at room temperature with gentle agitation and the signal was developed using Amersham ECL Prime WB substrate (GE Healthcare, Scottsdale, AZ, USA; #RPN2236) or SigmaFast BCIP/NBT substrate (Sigma Aldrich, St Louis, MO, USA; #B5655) for horseradish peroxidase or alkaline phosphatase conjugates, respectively. WB analysis of phospho-signaling downstream of CDCP1 was conducted 48 h post transfection: cells were serum starved for 6 h and then stimulated for 20 min with 10% FBS (Gibco, Carlsbad, CA, USA; #16000-044-1399) before lysing. All antibodies used for WB are listed in Supplementary Table 2. Construction of shRNA and cDNA overexpression constructs for CDCP1 pLM-CMV-flCDCP1 was cloned by PCR using pDrive-flCDCP1 (OpenBiosystems, Huntsville, AL, USA; #IHS1382-8427202) as a template. As pDrive-flCDCP1 contained five mismatches when aligned to WT CDCP1 referenced in Cosmic database, all mismatches in pLM-CMV-flCDCP1 were reverted to WT sequence using the Lightning Site Directed Mutagenesis kit (Stratagene, Santa Clara, CA, USA; #210516).
pLM-CMV-flCDCP1-Flag and pLM-CMV-flCDCP1-His were cloned by PCR using pLM-CMV-flCDCP1 as a template.
pLM-CMV-cCDCP1-Flag and pLM-CMV-cCDCP1-His were cloned in two steps. First, cCDCP1 was amplified by PCR using pLM-CMV-flCDCP1 as a template. Second, the SP was cloned upstream of cCDCP1 by PCR using pLM-CMV-flCDCP1 as a template.
pLM-CMV-cCDCP1-Y734F-Flag and pLM-CMV-cCDCP1-Y734F-His were generated from pLM-CMV-cCDCP1-Flag and pLM-CMV-cCDCP1-His by sitedirected mutagenesis using the Lightning Site Directed Mutagenesis kit (Stratagene).
pLM-CMV-ECC-His was cloned by PCR using pLM-CMV-flCDCP1 as a template.
pLM-CMV-cCDCP1-N'luc, pLM-CMV-cCDCP1-C'luc, pLM-CMV-flCDCP1-N'luc and pLM-CMV-flCDCP1-C'luc were cloned in two steps. First, N'luciferase and C'luciferase were PCR amplified from the constructs described by Choi et al. 34 Second, cCDCP1 and flCDCP1 were cloned upstream of N'luc and C'luc. cCDCP1 was amplified from pLM-CMVcCDCP1-Flag, which had already an SP. flCDCP1 was amplified from pLM-CMV-flCDCP1.
To make shRNA-insensitive flCDCP1 (pLM-CMV-sh-ins-flCDCP1), the third nucleotides of each codon in the regions of flCDCP1 recognized by the shRNAs were mutated to interfere with shRNA binding but carefully maintain WT flCDCP1 protein sequence. The 985-bp sh-ins-CDCP1 fragment with NheI and BamHI restriction sites at the 5′-and 3′-ends, respectively, was synthetized by GenScript (Piscataway, NJ, USA) and cloned to pUC57 by EcoRV. The fragment (+1 to +650 bp downstream of the start codon) was cloned to pLM-CMV-flCDCP1 by NheI and BamHI restriction sites.
To make shRNA-insensitive ncCDCP1 (pLM-CMV-sh-ins-ncCDCP1), the cleavage site in pLM-CMV-sh-ins-flCDCP1 was mutated: RK368-9QN. A gBlock containing CDCP1 fragment flanking the cleavage site (+977 to +1257 bp downstream of the start codon) with BamHI and AgeI was synthesized. This gBlock was cloned into pLM-CMV-sh-ins-flCDCP1 by BamHI and AgeI restriction sites.
Each construct originally had a puromycin resistance cassette. Puromycin was replaced with hygromycin and neomycin in pLM-CMV-cCDCP1-His and pLM-CMV-sh-ins-ncCDCP1, respectively. Hygromycin and neomycin resistance cassettes were obtained from pLM-CMV-H4-hygro and pLM-CMV-H4-neo plasmids using the SpeI and SalI restriction enzymes and cloned into SpeI-and SalI-digested pLM-CMV-cCDCP1-His and pLM-CMVsh-ins-ncCDCP1, respectively.
pLKO.1shCDCP1-1 was purchased from OpenBiosystems (#RHS3979-98822176). pLKO.1shScrambled was purchased from Addgene (Cambidge, MA, USA; #1864). pLKO.1shCDCP1-7 was cloned using two annealed complimentary oligos and ligated to AgeI-and EcoRI-digested pLKO.1 empty vector (Addgene #8453).
All oligonucleotides and gBlocks in this section were synthesized by IDT (Coralville, IA, USA) and are all listed in the Supplementary Table 3. Cell transfections with overexpression constructs HEK 293T cells were transfected using Lipofectamine and Plus reagents (Life Tech, Carlsbad, CA, USA; #18324-012 and #11514-015) following the manufacturer's protocol and used for experiments 2-3 days post transfection.
Virus production and infection of target cells Detailed protocol is described in Razorenova et al. 52 To produce virus, HEK 293T cells were transfected with each lentiviral plasmid along with packaging plasmids, pVSVG and ΔR8.2 using standard CaCl 2 transfection protocol. Virus-containing media with 6 μg/ml polybrene filtered through a 0.45-μm PES filter was transferred to TNBC target cells, which were selected in antibiotic-containing media for minimum 1 week.
ECC detection in cell media
HEK 293T were transfected with pLM-CMV-ECC-His using Lipofectamine and Plus reagents following the manufacturer's protocol (Life Tech) in a sixwell plate. Twenty-four hours after transfection, the media was changed to 1 ml fresh DMEM with 10% FBS. Forty-eight hours later, 50 μl of media was collected and denatured in 12.5 μl 5 × sample loading buffer (312 mM Tris-HCl pH 6.8, 10% SDS, 0.05% bromophenol blue, 50% glycerol, 10% β-mercaptoethanol). Samples were analyzed by WB.
Quantitative reverse transcriptase-PCR
Quantitative reverse transcriptase-PCR was performed as previously described 10 using the ViiA 7 Real-Time PCR System (Life Tech). Human cCDCP1 activity depends on homodimerization HJ Wright et al TATA-binding protein primers were chosen as an internal control. Primers are listed in Supplementary Table 3 .
Immunocytochemistry Cells were fixed with 4% paraformaldehyde for 10 min, then treated with 0.3% Triton X-100 in 1 × PBS for 5 min before blocking for 1 h in 5% bovine serum albumin in 1 × PBS. Cells were then incubated overnight in primary antibody at 4°C, followed by incubation for 2 h in secondary antibody at room temperature in the dark. Antibodies used are listed in Supplementary  Table 2 . Both primary and secondary antibodies were diluted in 1% bovine serum albumin in 1 × PBS. Cell nuclei were counterstained with Hoechst 33342 at 1:500 in 1 × PBS for 1 min. Coverslips were mounted with Vectashield (Vector #H-1000) and imaged using a Nikon Eclipse Ti microscope with a 40 × or 63 × objective and NIS element AR3.10 software. Images for sh-ins-ncCDCP1-transfected HEK 293T cells were taken using a Zeiss Spinning Disc Confocal Microscope (Zeiss, Pleasanton, CA, USA) with a 63 × objective and AxioVision software (Zeiss).
Duolink proximity ligation assay
The assay was performed according to the manufacturer's protocol (Sigma Aldrich; #DUO92008, #DUO92009 and #DUO92010). Primary antibody probes were made using goat anti-CDCP1 antibody (Abcam, Cambridge, MA, USA; #ab1377). Images were collected as for immunofluorescence staining analysis. Twelve-millimeter coverslips were used with 20 μl reaction volumes.
Co-immunoprecipitation
Four hundred micrograms of protein in 200 μl of cell lysis buffer (see recipe in 'Primary specimen acquisition and lysis') was incubated with 4 μl of antiFlag antibody (Sigma Aldrich; #F1804) for 16 h at 4°C with gentle agitation. Then, 20 μl Protein G Dynabeads (Life Tech; #10003D) were added, followed by incubation for 1 h at 4°C. Immunoprecipitated proteins were collected using magnetic stand, washed three times for 5 min on ice with cell lysis buffer without protease or phosphatase inhibitors, boiled in 1 × sample loading buffer for 6 min and analyzed by WB.
Transwell migration
Transwell inserts (Corning Life Sciences Plastic, Corning, NY, USA; #3464) were coated in 50 mg/ml fibronectin (Sigma Aldrich; #F2006-2) in DMEM for 4 h at 37°C. Cells were treated with 100 μM mitomycin C for 2.5 h before being detached with 2% EDTA in 1 × PBS. Sixty thousand HEK 293T, MDA-MB-468, and UCI-082014 cells in serum-free DMEM were added to the top chamber of the inserts immersed in 10% FBS-containing media in the bottom chamber. Cells were allowed to migrate for 24 h (HEK 293T), 16 h (MDA-MB-468), and 6 h (UCI-082014). Cells from the top of the transwell inserts were removed with a cotton swab and cells that migrated through the transwell inserts were fixed and stained using the Richard Allen 3
Step Staining Kit (Thermo Scientific, Grand Island, NY, USA; #3300), photographed and counted.
Scratch assay
MDA-MB-231 cells (2 00 000) were plated per well in a 6-well plate. Twenty-four hours later, cell monolayers were treated with mitomycin C for 2 h in serum-free DMEM and then scratched with a 200-μl pipette tip. The bottom of the plate was marked at three points on the scratch for triplicate measurements. Cells were washed once with 1 × PBS and incubated in DMEM with 2% FBS, 2 mM L-glutamine, 100 μg/ml penicillin and 100 μg/ml streptomycin. Pictures of the scratch were taken at the time of the scratch (T 0 ) and at 6 h after the scratch (T 6 ). Percent wound closure was calculated as (1 − (T 6 /T 0 ))*100.
Split-luciferase assay HEK 293T cells were plated at 10 000 cells per well in a black-walled 96-well plate. Sixteen hours later, they were transfected with CDCP1-N'luc, CDCP1-C'luc and either a VC or ECC using Lipofectamine and Plus reagents (Life Tech) following the manufacturer's protocol. Forty-eight hours after transfection, dimerization was analyzed with D-luciferin (Promega, Madison, WI, USA; #E1605) on an IVIS Lumina Imager (PerkinElmer, Waltham, MA, USA).
3D assays MDA-MB-231, MDA-MB-468 and UCI-082014 cell lines were plated at 3000 cells in 50 μl of 1:1 collagen (BD Biosciences, Franklin Lakes, NJ, USA; #354249):Matrigel (BD Biosciences; #356234) gel. Collagen was initially prepared at 6.4 mg/ml according to the manufacturer's protocol before being mixed with Matrigel for a final concentration in the gels of 3.2 mg/ml collagen, similar to that in transformed breast tissue. 53, 54 Gels were plated onto 12-mm coverslips. Media on the cells was changed every 2 days and cells were allowed to proliferate/invade the gel for 6 days. Gels were fixed in 4% paraformaldehyde for 20 min, washed 4 × 15 min with 1 × PBS, permeabilized with 0.3% Triton X-100 in 1 × PBS for 15 min, washed 4 × 15 min with 1 × PBS, incubated in blocking solution (10% donkey serum, 5% bovine serum albumin, 0.1% Triton X-100 in 1 × PBS) overnight at 4°C with gentle agitation. Antibodies used for fluorescent staining in 3D are provided in Supplementary Table 2 . Phase-contrast images were taken using an EVOS × L Microscope (AMG, Bothell, WA, USA) with a 10 × objective. Fluorescent images were taken using a Zeiss Spinning Disc Confocal Microscope with a 20 × objective with numerical aperture 0.8 and AxioVision software. Quantification was the average of five images/gel for three biological replicates.
